Quince Therapeutics regains Nasdaq bid-price compliance

Quince Therapeutics, Inc. reports that Nasdaq has informed the company it has regained compliance with the Nasdaq Global Select Market minimum bid price requirement under Listing Rule 5450(a)(1).

Rhea-AI Filing Summary

Quince Therapeutics, Inc. reports that Nasdaq has informed the company it has regained compliance with the Nasdaq Global Select Market minimum bid price requirement under Listing Rule 5450(a)(1). The company’s common stock closed at $1.00 or more for 10 consecutive business days from April 13 through April 24, 2026.

The company remains out of compliance with Nasdaq’s market value of listed securities requirement under Listing Rule 5450(b)(2)(A), which requires at least $50,000,000. Quince has until September 14, 2026 to regain compliance with this MVLS requirement, and there is no assurance it will do so or maintain compliance with other listing standards.

Insights

Equity listing & markets analyst

Quince restores Nasdaq bid-price compliance but still faces MVLS hurdle.

Quince Therapeutics has cleared one key Nasdaq standard: its stock traded at or above $1.00 for 10 consecutive business days, restoring compliance with Listing Rule 5450(a)(1). This removes the immediate risk tied to the minimum bid price test.

The remaining issue is Nasdaq’s market value of listed securities requirement of at least $50,000,000 under Listing Rule 5450(b)(2)(A). Quince has until September 14, 2026 to meet this, and the company explicitly notes there is no assurance it will regain or maintain full listing compliance. The overall impact is mixed: near-term relief on bid price, but continued listing risk tied to MVLS.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Minimum bid price threshold: $1.00 per share Consecutive days at or above $1.00: 10 business days MVLS requirement: $50,000,000 +2 more

5 metrics

Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5450(a)(1) requirement

Consecutive days at or above $1.00 10 business days April 13–24, 2026 closing bid prices

MVLS requirement $50,000,000 Nasdaq Listing Rule 5450(b)(2)(A) threshold

Initial MVLS deficiency period 30 consecutive business days Market value of listed securities below $50,000,000

Compliance deadline for MVLS September 14, 2026 End of 180 calendar day cure period

Key Terms

minimum bid price requirement, market value of listed securities, Nasdaq Global Select Market, Listing Rule 5450(a)(1), +1 more

5 terms

minimum bid price requirement financial

"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

market value of listed securities financial

"the Company’s market value of listed securities (“MVLS”) for the last 30 consecutive business days was less than the $50,000,000 required"

Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.

Nasdaq Global Select Market financial

"required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A)"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Listing Rule 5450(a)(1) regulatory

"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1)"

Listing Rule 5450(b)(2)(A) regulatory

"required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”)"

FAQ

What Nasdaq compliance update did Quince Therapeutics (QNCX) disclose?

Quince Therapeutics disclosed it regained compliance with Nasdaq’s minimum bid price rule, as its stock closed at $1.00 or more for 10 consecutive business days. However, it is still not in compliance with Nasdaq’s market value of listed securities requirement.

How did Quince Therapeutics regain Nasdaq minimum bid price compliance?

Quince regained compliance because its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days, from April 13 through April 24, 2026. Nasdaq’s Listing Qualifications staff confirmed this satisfied Listing Rule 5450(a)(1).

Which Nasdaq listing requirement does Quince Therapeutics (QNCX) still fail to meet?

Quince remains out of compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires a market value of listed securities of at least $50,000,000. The company previously received an MVLS notice reflecting that its market value had been below this threshold for 30 consecutive business days.

How long does Quince Therapeutics have to fix its Nasdaq MVLS deficiency?

Quince Therapeutics has 180 calendar days, until September 14, 2026, to regain compliance with Nasdaq’s market value of listed securities requirement. If it does not meet the $50,000,000 MVLS threshold by then, additional Nasdaq actions regarding its listing status could follow.

Does regaining the minimum bid price guarantee Quince Therapeutics stays on Nasdaq?

Regaining the minimum bid price requirement closes that specific issue but does not guarantee continued listing. Quince still must satisfy Nasdaq’s $50,000,000 market value of listed securities requirement and acknowledges there is no assurance of regaining or maintaining full listing compliance.

What stock market is Quince Therapeutics’ common stock listed on?

Quince Therapeutics’ common stock is listed on the Nasdaq Global Select Market under the trading symbol QNCX. The company’s listing is subject to meeting Nasdaq’s continued listing standards, including minimum bid price and market value of listed securities requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:30 PM Learn about SEC filing dates

false 0001662774 0001662774 2026-04-27 2026-04-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38890		90-1024039
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

611 Gateway Boulevard, Suite 273
South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On April 27, 2026, Quince Therapeutics, Inc. (the “Company”), received a letter from the Nadsaq Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). The letter noted that for the 10 consecutive business days from April 13, 2026 through April 24, 2026, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and Nasdaq considers this matter closed.

As previously disclosed, the Company previously received a notice (the “MVLS Notice” and together with the Bid Price Notice the “Notices”) from the Staff that the Company’s market value of listed securities (“MVLS”) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Company has not yet regained compliance with the MVLS Requirement and has a period of 180 calendar days, or until September 14, 2026, to regain compliance with the MVLS Requirement. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Quince Therapeutics, Inc.
				By:		/s/ Dirk Thye
Date: April 28, 2026				Name:		Dirk Thye
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB